Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Skinvisible Pharmaceuticals publishes groundbreaking research on transdermal obesity drug delivery using Invisicare technology. The study shows 99.6% transdermal penetration of GLP-1 actives, offering a non-invasive alternative to injections. Skinvisible seeks partnerships to bring transdermal obesity therapies to market.
